2007. The effectiveness and safety, and appropriate dosing of atypical antipsychotics in preschool children remain unknown. Adverse effects have been documented in the literature (even at low doses) including: excessive weight gain and obesity, increases in prolactin, and extrapyramidal side effects. The effect of antipsychotics on the neurodevelopment of young children is also unknown. Anxiety Measures 24. Pharmacotherapy with % of enrollees 18 years of age Numerator: Those children in the SSRIs are the first-line medication Medicaid Claims & Encounter A SSRIs for anxiety or younger with a new episode denominator with at least one treatment for childhood anxiety Data disorders of anxiety disorder who received prescription for an SSRI medication disorders. AACAP practice Pharmacy Files at least one prescription for an guidelines recommend Eligibility Files selective serotonin reuptake Denominator: The number of pharmacological interventions when Professional Files inhibitor (SSRI) within the 84 children (≤ 18 years of age) with anxiety symptoms are moderate or days (12 weeks) of the initial continuous enrollment and a new severe and/or in instances of partial diagnosis diagnosis for anxiety disorder who response to psychotherapy. Multiple had at least one prescription for a RCTs have demonstrated the psychotropic medication during the efficacy of SSRIs for the 84 day (12 week) acute treatment treatment of childhood phase. anxiety disorders, including: GAD, social phobia, and SAD. SSRIs are See Appendix F for listing of SSRI also well tolerated in children and antidepressants adolescents with anxiety disorders. 25. Chronic use of % of enrollees 18 years of age Numerator: Those children in the Reports from the literature suggest a Medicaid Claims & Encounter B benzodiazepine or younger with a mental health denominator with continuous nearly threefold increase in use of Data diagnosis who used benzodiazepine treatment (≥ 60 days anxiolytics for children and Pharmacy Files (All diagnoses) benzodiazepines for ≥ 60 days of use) adolescents during the past decade. Eligibility Files or more Despite this trend, the literature Professional Files Denominator: The number of supporting the therapeutic role of children (≤ 18 years of age) who benzodiazepines in children is were continuously enrolled and had a sparse. The safety and efficacy of
2007. The effectiveness and safety, and appropriate dosing of atypical antipsychotics in preschool children remain unknown. Adverse effects have been documented in the literature (even at low doses) including: excessive weight gain and obesity, increases in prolactin, and extrapyramidal side effects. The effect of antipsychotics on the neurodevelopment of young children is also unknown. Anxiety Measures 24. Pharmacotherapy with SSRIs for anxiety disorders % of enrollees 18 years of age or younger with a new episode of anxiety disorder who received at least one prescription for an selective serotonin reuptake inhibitor (SSRI) within the 84 days (12 weeks) of the initial diagnosis Numerator: Those children in the denominator with at least one prescription for an SSRI medication Denominator: The number of children (≤ 18 years of age) with continuous enrollment and a new diagnosis for anxiety disorder who had at least one prescription for a psychotropic medication during the 84 day (12 week) acute treatment phase. See Appendix F for listing of SSRI antidepressants SSRIs are the first-line medication treatment for childhood anxiety disorders. AACAP practice guidelines recommend pharmacological interventions when anxiety symptoms are moderate or severe and/or in instances of partial response to psychotherapy. Multiple RCTs have demonstrated the efficacy of SSRIs for the treatment of childhood anxiety disorders, including: GAD, social phobia, and SAD. SSRIs are also well tolerated in children and adolescents with anxiety disorders. Medicaid Claims & Encounter Data Pharmacy Files Eligibility Files Professional Files A 25. Chronic use of benzodiazepine (All diagnoses) % of enrollees 18 years of age or younger with a mental health diagnosis who used benzodiazepines for ≥ 60 days or more Numerator: Those children in the denominator with continuous benzodiazepine treatment (≥ 60 days of use) Denominator: The number of children (≤ 18 years of age) who were continuously enrolled and had a Reports from the literature suggest a nearly threefold increase in use of anxiolytics for children and adolescents during the past decade. Despite this trend, the literature supporting the therapeutic role of benzodiazepines in children is sparse. The safety and efficacy of Medicaid Claims & Encounter Data Pharmacy Files Eligibility Files Professional Files B
QualityMeasures.docx